Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Top Cited Papers
- 23 December 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (26) , 2487-2498
- https://doi.org/10.1056/nejmoa1006885
Abstract
There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use.This publication has 20 references indexed in Scilit:
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialPublished by Elsevier ,2009
- Editorial BoardThe Journal of Arthroplasty, 2009
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialPublished by Elsevier ,2008
- Prevention of Venous ThromboembolismChest, 2008
- Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJournal of Thrombosis and Haemostasis, 2008
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007